Emerging drugs for ichthyosis.
The ichthyoses constitute a large and heterogeneous group of disorders characterised by varying degrees of skin scaling. Most forms are rare but between them, they affect tens of thousands of people worldwide. Treatment presently consists primarily of topical keratolytic agents, aimed at removing the ichthyotic scales, and emollients. If an ichthyosis cannot be controlled by topical therapy alone, retinoids can be used. Although effective in several forms of ichthyosis, side effects and teratogenicity severely limit their use. The recent development of retinoic acid metabolism blocking agents (RAMBAs) offers new possibilities. With these drugs, retinoid effects may be obtained with less side effects and a shorter post-treatment teratogenicity period. This review discusses the RAMBAs that are now in clinical trials and outlines possible future developments.
van Steensel
M A M
MA
University of Maastricht, Department of Dermatology, University Hospital Maastricht and GROW Research School, PO Box 5800, 6202 AZ Maastricht, The Netherlands. mauricevansteensel@gmail.com
D000818:Animals; D015195:Drug Design; D006801:Humans; D007057:Ichthyosis / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D007093:Imidazoles / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D015394:Molecular Structure; D014212:Tretinoin / Q000009:adverse effects / Q000378:metabolism* / Q000627:therapeutic use
D007093:Imidazoles; D007641:Keratolytic Agents; D014212:Tretinoin; C061121:liarozole